Sorry, you need to enable JavaScript to visit this website.


野生型转甲状腺素蛋白淀粉样变性心肌病(wtATTR-CM)的风险估算工具

wtATTR-CM风险评估

wtATTR-CM是引发心衰的原因之一,但尚未被认知。如不及时治疗患者预后将迅速恶化,早期诊断至关重1,2

wtATTR-CM estimATTR工具能够通过以下形式突出心脏或非心脏症状相结合的情况,由此引起对于wtATTR-CM的怀疑

  • 基于已知与疾病相关的临床特征组合估计wtATTR-CM的可能性
  • 说明有助于通过重要特征区分wtATTR-CM和其他原因引起的心力衰竭

关于这个估算工具

wtATTR-CM estimATTR是基于人工智能/机器学习(AI/ML算法开发的,使用从真实世界获取的大量诊断代码,其数据集包括了1678名wtATTR-CM患者

了解更多关于方法学参考文献

  • 支持主要算法
  • 支持将算法应用到wtATTR-CM estimATTR

关键注意事项

  1. wtATTR-CM estimATTR仅用于教育目的,不得用于临床环境中个体患者的疑似或诊断wtATTR-CM
  2. wtATTR-CM estimATTR不能评估遗传性ATTR-CMhATTR-CM)或其他类型的心脏淀粉样变性,如轻链(AL)淀粉样变性或更罕见的心脏淀粉样变性类型,如载脂蛋白A1(ApoA1)、淀粉样A蛋白(AA)、凝溶胶蛋白等。
  3. 当怀疑有心脏淀粉样变性时,首先排除AL淀粉样变性至关重要,因为该病为血液科急重症,且治疗方案不同于wtATTR-CM3

开始

确认并接受以下内容以开始使用工具:

参考文献

A Machine Learning Model for the Systematic Identification of Wild-Type Transthyretin Cardiomyopathy (HFSA Abstract and Poster 137)

作者:Ahsan Huda, Sanjiv J. Shah, Adam Casta√±o, Anindita Niyogi, Jennifer Schumacher, Michelle Stewart, Rahul Deo

Presented at the 2019 Heart Failure Society of America 23rd Annual Scientific Meeting; September 13-16, 2019; Philadelphia, Pennsylvania.

A Machine Learning Framework for Predicting Risk of Wild-Type Transthyretin Amyloid Cardiomyopathy (ISA Abstract 339 and Poster PW088)

作者:Ahsan Huda, Stephen Heitner, Veena Calambur, Marianna Bruno, Jennifer Schumacher, Birol Emir, Catherine Isherwood, Adam Casta√±o

Presented at the XVII International Society of Amyloidosis Symposium; September 14-18, 2020; virtual.

1. Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014;2(2):113-122. 
2. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357-1377. 
3. Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2—evidence base and standardized methods of imaging [published online ahead of print August 29, 2019]. J Nucl Cardiol. doi:10.1007/s12350-019-01760-6.